Combined α-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: A prospective randomized trial

W. Scheithauer, A. Cortelezzi, E. Fritz, I. Kuhrer, E. Polli, L. Baldini, H. Ludwig

Research output: Contribution to journalArticle

Abstract

Thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-α-2C (rIFN-α-2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP chemotherapy alone. The combined regimen effected 67% responses and 26% minor responses, while 35 and 47% of VMCP-treated patients had a pathologically documented remission, respectively. Despite the somewhat earlier achievement and duration (12.0 vs. 8.0 months) of objective response, and the marginal survival benefit observed in the rIFN-α-2C + VMCP treatment arm, a significant improvement in therapeutic gain by adding a biologic response modifier to conventional first-line polychemotherapeutic drug treatment in myeloma patients has not yet been achieved. The combined regimen was well tolerated without unusual or unexpected toxic effects.

Original languageEnglish
Pages (from-to)109-115
Number of pages7
JournalJournal of Biological Response Modifiers
Volume8
Issue number2
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Combined α-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: A prospective randomized trial'. Together they form a unique fingerprint.

  • Cite this